Ajanta Pharma vs RUBICON RESEARCH: Share Price, Valuation and Results Compared

Ajanta Pharma Limited (NSE: AJANTPHARM) and RUBICON RESEARCH LIMITED (NSE: RUBICON) are both listed in the Pharmaceuticals industry. Ajanta Pharma has a market capitalisation of ₹41,474 Cr and RUBICON RESEARCH ₹28,526 Cr, as of 16 Nov 2026. Their P/E ratios are 39.4 and 112.3 respectively. Return on equity is 25.39% for Ajanta Pharma and 19.14% for RUBICON RESEARCH. Over one year, Ajanta Pharma's share price is up 27.8% and RUBICON RESEARCH's is up 162.7%.

Ajanta Pharma vs RUBICON RESEARCH — Key Figures

MetricAjanta PharmaRUBICON RESEARCH
NSE SymbolAJANTPHARMRUBICON
BSE Code532331544578
Share Price₹3,279.00₹1,675.00
Market Cap₹41,474 Cr₹28,526 Cr
P/E Ratio39.4112.3
Return on Equity25.39%19.14%
Return on Assets14.85%11.74%
Dividend Yield1.92%0.09%
Beta (1Y)0.190.11
1-Year Price Change+27.8%+162.7%
3-Month Price Change-9.1%+3.5%
52-Week Range₹2,445.80 – ₹3,796.00₹615.20 – ₹1,899.00
Latest QuarterQ2 FY27Q2 FY27
Quarterly Revenue₹1,794 Cr₹576 Cr
Quarterly Net Profit₹388 Cr₹90 Cr
Net Margin21.6%15.7%
EPS (Basic, Quarter)₹31.07₹5.47
Results Basisconsolidatedconsolidated
HeadquartersMumbai, MaharashtraMumbai, Maharashtra

The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.

About the Companies

Ajanta Pharma Limited

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 19…

RUBICON RESEARCH LIMITED

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabol…

Frequently Asked Questions

Which is larger by market cap, Ajanta Pharma or RUBICON RESEARCH?

Ajanta Pharma has a market capitalisation of ₹41,474 Cr, against ₹28,526 Cr for RUBICON RESEARCH as of 16 Nov 2026, about 1.5 times the size by market cap.

What is the P/E ratio of Ajanta Pharma and RUBICON RESEARCH?

Ajanta Pharma has a P/E of 39.4 and RUBICON RESEARCH a P/E of 112.3 as of 16 Nov 2026.

What is the return on equity of Ajanta Pharma and RUBICON RESEARCH?

Ajanta Pharma has a return on equity of 25.39% and RUBICON RESEARCH 19.14%.

How have Ajanta Pharma and RUBICON RESEARCH shares moved over one year?

Ajanta Pharma's share price is up 27.8% over one year and RUBICON RESEARCH's is up 162.7%.

What were the latest quarterly results of Ajanta Pharma and RUBICON RESEARCH?

Ajanta Pharma reported revenue of ₹1,794 Cr and net profit of ₹388 Cr for Q2 FY27. RUBICON RESEARCH reported revenue of ₹576 Cr and net profit of ₹90 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.

Which industry are Ajanta Pharma and RUBICON RESEARCH in?

Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.

Is this comparison a recommendation to buy or sell Ajanta Pharma or RUBICON RESEARCH?

No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.

More Comparisons

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.